Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol vs Calcitriol for CAD and CRS in Renal Transplant Recipients
NCT01265615Phase 4Completed
- Sponsor
- Ural State Medical University
- Start
- Oct 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of paricalcitol oral solution in chronic allograft dysfunction (CAD) and cardiorenal syndrome (CRS) (4 arms), sponsored by Ural State Medical University. Primary endpoint: Chronic Allograft Dysfunction Degree at 180 days. Started Oct 2009; status: completed.
02
Drugs
paricalcitol oral solution
03
Conditions
chronic allograft dysfunction (CAD)cardiorenal syndrome (CRS)
Beyond the preview
Go deeper on NCT01265615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265615.